Navigation Links
SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Date:9/16/2008

ourth quarter of 2008. Prior to proceeding with the trial the company must await clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. SemBioSys' planned Phase I/II human clinical trial is designed to enroll up to 30 healthy volunteers in a three-arm study to demonstrate the bioequivalence of safflower-produced insulin to comparator insulin products. The European authorities are the first major healthcare regulators to have published guidance documents that ensure insulin is eligible to receive approval through an abbreviated regulatory path. Separately, the U.S. FDA has advised SemBioSys that safflower-produced insulin is eligible to receive approval through an abbreviated 505(b)(2) approval process.

The world market value for insulin is estimated to be in excess of US$7.1 billion today and the demand for insulin is projected to increase due to two factors. The growing incidence of diabetes combined with the expanded use of insulin therapy is expected to almost double insulin demand over the next five years and increase the global insulin market to over $15 billion by 2012. SemBioSys' plant-made insulin is expected to offer substantial capital and cost-of-goods reductions with the potential to enter the market as a low-cost, easily expandable source of insulin to meet exploding global demand.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AIMilano, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys and its subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of non-pharmaceutical products addressing human topical, nutritional
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , Apr. 21, 2015 Research and Markets ... addition of the "Complete 2015-16 Induced Pluripotent ... their offering. Stem cell research and ... five decades, as stem cells have the unique ... their unspecialized nature allows them to differentiate into ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... Dr. Mark W. Sawicki , Chief ... Annual BioLogistics Summit in San Francisco, ...
(Date:4/21/2015)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before market open on Tuesday, April 28, 2015. ... on Tuesday, April 28, 2015, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
Breaking Biology Technology:Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO ... FOR CARDIOVASCULAR INFLAMMATION, DENVER, March 18 ... a worldwide developer and marketer of,diagnostic test ... the Okayama,Prefecture Industrial Promotion Foundation covering new ...
... 18 Visionsense Corp. announces,FDA 510(k) Clearance ... Vision,System. The system is based on a ... targeting Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... enhances MIS surgical,procedures that are under served ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
Cached Biology Technology:Corgenix Signs Technology Licensing Agreement With Japanese Government 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus (HCV) are at an increased risk of developing ... a study published in the May 8, 2007, issue ... Researchers from the National Cancer Institute (NCI), part of ... Medicine, found that HCV infection increased the risk of ...
... certain neurodegenerative diseases, such as mad cow disease or ... of infectious protein called a prion. Remarkably, in recent ... beneficial roles in biology, and prions even may act ... , But although prions have received a great deal ...
... central Catalonia, is so delicate that experts cannot get physically ... the years since the tracks were discovered they have been ... weathered and eroding at a rapid rate. , To ... near-vertical rock faces. , Palaeontologists feared the tracks could ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Diminishing dinosaur steps saved by laser and laptop 2Diminishing dinosaur steps saved by laser and laptop 3
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: